DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young brain tumor patients: experimental drug combo enters trials
Disease control Not yet recruitingThis study tests whether adding an experimental drug (ADI-PEG 20) to standard radiation and chemotherapy can help children, teens, and young adults with newly diagnosed high-grade glioma. About 97 participants will receive the drug combination to see if it is safe and delays tumo…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Nasal spray could deliver brain tumor treatment to kids
Disease control Not yet recruitingThis early-phase study tests a nasal spray called NEO100 in 12 children with specific, hard-to-treat brain tumors. The main goals are to check safety, find the best dose, and see if the drug reaches the tumor. It is a first step to see if this approach is safe enough for larger s…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC